Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest
- PMID: 40456239
- DOI: 10.1016/S2213-2600(25)00122-5
Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest
Abstract
When conventional cardiopulmonary resuscitation (CCPR) cannot restore spontaneous circulation, the initiation of venoarterial extracorporeal membrane oxygenation during refractory cardiac arrest-known as extracorporeal CPR (ECPR)-might restore circulation and adequate tissue oxygenation. ECPR could substantially improve survival with favourable functional recovery. However, the complexity and time-sensitive nature of the intervention, high costs, resource demands, considerable risks, and complications restrict the availability of ECPR. Patient age and comorbidities, timely and effective CCPR, and time-to-ECPR are major contributors to the outcome of patients. The primary goal of ECPR is full recovery of the patient, but in some cases, transition to a long-term ventricular assist device or heart transplantation can be additional options for survival. In patients diagnosed with brain death or, according to local regulation, in those with irreversible post-anoxic brain damage, organ donation is possible after ECPR. Ongoing research aims to assess the efficacy of ECPR versus continued CCPR and uncover key prognostic indicators.
Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests AS reports research grants from CytoSorbents Europe; honoraria for lectures from CytoSorbents Europe, AstraZeneca, Getinge, and Resuscitec; travel support from ARTCLINE; and consulting fees from ARTCLINE and LAUDA Medical, all outside of the submitted work. JB reports honoraria for lectures from Abiomed, Getinge, and Resuscitec. AC reports honoraria for lectures from Getinge and Baxter. AH reports travel support from Resuscitec. RL reports research grants from Medtronic and LivaNova, paid to his instititution; consulting fees from Medtronic and Liva Nova; membership of the medical advisory boards for Eurosets, Xenios, and Hemocue, with payments to their institution; material for experimental procedures from Medtronic; and personal honoraria for lectures from Abiomed. MvdP reports research funding from Getinge. DLS reports honoraria for lectures from Abiomed, AstraZeneca, Dahlhausen, Getinge, Medtronic, and Orion Pharma; and support for attending meetings from Abiomed, Getinge, Medtronic, and Orion Pharma. FST consults for EUROSETS and XENIOS. DB consults for LivaNova; has been on the medical advisory boards for Medtronic, Inspira, Cellenkos, HBOX Therapies, and Vantive; is President of the Extracorporeal Life Support Organization and Chair of the board of the International Extra-Corporeal Membrane Oxygenation Network; and writes for UpToDate. All other authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
